天邦股份(002124.SZ)：與南京星甸街道辦簽訂生物醫藥產業化基地投資協議
格隆匯 11 月 11日丨天邦股份(002124.SZ)公告，公司與南京市浦口區人民政府星甸街道辦事處（以下簡稱“星甸街道辦”、“甲方”）就公司在南京市浦口區星甸街道星甸工業園投資生物醫藥產業化基地項目達成協議。
本次協議暫未簽訂，具體簽訂日期將於董事會審議通過後確定，並待公司股東大會審議通過後生效。本協議不構成關聯交易，需提交股東大會審議，不構成《上市公司重大資產重組管理辦法》規定的重大資產重組，公司將視後續進展履行審議及披露義務。
根據協議約定，公司需要註冊成立新公司負責協議項目的運營，擬註冊公司情況如下（最終以工商核定為準）：
1、擬註冊公司名稱：史記生物科技有限公司
2、企業類型：有限責任公司；
3、註冊資本：30,000 萬元；
4、公司住所：南京市星甸街道星甸工業園
5、經營範圍：動物疫苗、動物疫病診斷試劑、動物疫病檢測技術服務、獸醫技術服務、生物添加劑、動物繁殖激素、肝素鈉、生化原料等。
6、持股比例及出資方式：公司全資子公司史記生物技術（南京）有限公司出資 3 億元人民幣，公司 100%間接控股。
公司近 12 個月內已註冊且未披露的子公司註冊資本累計已達 25,800 萬元，加上本次擬註冊公司，累計註冊資本超過公司最近一期經審計淨資產 10%，本次註冊子公司事項已經公司第七屆董事會第二十七次會議審議通過。
此次與南京市浦口區人民政府星甸街道辦事處簽訂項目投資協議，是公司向產業鏈上下游延伸的進一步戰略佈局。
生物醫藥產業化基地項目將建成包括獸用滅活疫苗生產車間、獸用活疫苗生產車間、獸用診斷試劑車間、能源動力車間。肝素鈉精製純化車間、肝素鈉製劑車間、倉儲物流大樓、質量控制及研發中心大樓、行政大樓等。生物醫藥產業化基地落成後，將大幅度提升公司疫苗生產能力，對內可以匹配公司不斷增長的生豬養殖規模所帶來的內部供應需求，支持公司生豬養殖業務發展；對外，隨着新車間投產，公司的外銷疫苗品質提升，供應有保障，有助於塑造公司品牌力，增加市場份額佔有率。肝素鈉生產車間的建設，強化了公司生豬屠宰深加工業務能力，將深加工業務從食品加工領域拓展到生物製品生產領域，進一步向生豬產業鏈下游高科技產業延伸，提升公司盈利能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
